Next issueIssue 23 · Tue 17 Nov 

Six molecules·76 trial records·6 deals·21 calls on the record

Drug companies are spending billions on psychedelic medicine, mostly in America.

We read the contracts and filings behind every deal to show what's been bought, what's been skipped, and what that leaves open in Europe.

Free. One email, Tuesday 11:00. Unsubscribe in one click.

Six molecules will decide what Europe gets. We follow all of them, every week.

For the 21 million people in the EU living with depression.

The money

$8.2bn

Headline value of the six deals we track. Lilly, AbbVie, Otsuka. None of it European.

Where Europe stands

Twelve assets. Six molecules. Four with no European partner.

Every row from a filing or a registry. Stage is the highest with a European record; US progress is a note, never a position.

MoleculeAssetHolderStage in EuropeEuropean partnerBoughtSource
PsilocybinCOMP360Compass PathwaysPhase 3None disclosed·10-K · 25 Aug
LysergideDT120Definium TherapeuticsPhase 3None disclosed·10-K · 15 Sep
MebufoteninBPL-003Lilly, via AtaiBeckleyPhase 2Lilly$3.8bn · Sep 20268-K · 15 Sep
GH001GH ResearchPhase 2None disclosed·20-F · 25 Aug
HLP003HLP003Helus PharmaPhase 3None disclosed·AIF · 24 Aug
MDMAAmsterdam UMCInvestigator-ledPhase 2n/a·CTIS · 8 Sep
BrenipatideLY3537031LillyPhase 3Lilly·10-Q · 15 Sep

Issue 22·10 November 2026

EMBRACE has halted in every EU country where it started.

CTIS logs a temporary halt for the HLP003 Phase 3 in Poland, Greece and Ireland, dated 28 September, the day recruitment ended. The sponsor's justification: "Temporary interruption in IP supply, not quality related". Our call: no restart by 31 March.

Read the issue

For funds and corporate development teams: the Deal Read, 1,500 EUR. First page in 48 hours.

The call in this issue

EMBRACE will not restart in Poland, Greece or Ireland by 31 March 2027.

Open · resolves by 31 Mar 2027 · scored in the first May issue
Falsifier: CTIS shows RESTART_OF_TRIAL or RESTART_OF_RECRUITMENT for Poland, Greece or Ireland on record 2024-519270-40-00, with an event date on or before 31 March 2027, as published in CTIS when read on 30 April 2027

21calls16open3right2wrongThe ledger